Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence

Parkinsonism and Related Disorders

Volumn 21, Issue 12, 2015, Pages 1407-1414

  Pellegrini, Carolina ^a   Antonioli, Luca ^a   Colucci, Rocchina ^a   Ballabeni, Vigilio ^b   Barocelli, Elisabetta ^b   Bernardini, Nunzia ^a   Blandizzi, Corrado ^a   Fornai, Matteo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Gastric motility; Gastric neuromuscular functions; Parkinson's disease; Preclinical models of Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; NEURONAL NITRIC OXIDE SYNTHASE; OXIDOPAMINE; CHOLECYSTOKININ; PROTEIN AGGREGATE; ROTENONE;

ALPHA SYN GENE; AMINO ACID SUBSTITUTION; BIOACCUMULATION; DISEASE ASSOCIATION; DOPAMINERGIC TRANSMISSION; GASTRIC DYSMOTILITY; GASTRIC MOTOR DYSFUNCTION; GENE EXPRESSION REGULATION; GENETIC MODEL; HUMAN; INTESTINE INNERVATION; MOTOR DYSFUNCTION; MYENTERIC PLEXUS; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMACH DISEASE; STOMACH EMPTYING; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; COMPLICATION; EFFERENT NERVE; GASTROINTESTINAL MOTILITY; GASTROPARESIS; GENETICS; MOUSE; NEUROMUSCULAR JUNCTION; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; TRANSGENIC MOUSE; TRANSLATIONAL RESEARCH; VAGUS NERVE;

ALPHA-SYNUCLEIN; ANIMALS; CHOLECYSTOKININ; EFFERENT PATHWAYS; ENTERIC NERVOUS SYSTEM; GASTRIC EMPTYING; GASTROINTESTINAL MOTILITY; GASTROPARESIS; HUMANS; MICE; MICE, TRANSGENIC; MODELS, NEUROLOGICAL; NEUROMUSCULAR JUNCTION; OXIDOPAMINE; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PROTEIN AGGREGATES; RATS; ROTENONE; TRANSLATIONAL MEDICAL RESEARCH; VAGUS NERVE;

EID: 84955702998     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.10.011     Document Type: Review

References (70)

1. Goetze O., Nikodem A.B., Wiezcorek J., Banasch M., Przuntek H., Mueller T., Schmidt W.E., Woitalla D. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol. Motil. 2006, 18:369-375.
2. Djaldetti R., Baron J., Ziv I., Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996, 46:1051-1054.
3. Marrinan S., Emmanuel A.V., Burn D.J. Delayed gastric emptying in Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. 2014, 29:23-32.
4. Hardoff R., Sula M., Tamir A., Soil A., Front A., Badarna S., Giladi N. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov. Disord. 2001, 16:1041-1047.
5. Edwards L.L., Quigley E.M., Harned R.K., Hofman R., Pfeiffer R.F. Characterization of swallowing and defecation in Parkinson's disease. Am. J. Gastroenterol. 1994, 89:15-25.
6. Sung H.Y., Park J.W., Kim J.S. The frequency and severity of gastrointestinal symptoms in patients with early Parkinson's disease. J. Mov. Disord. 2014, 7:7-12.
7. Braak H., de Vos R.A., Bohl J., Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 2006, 396:67-72.
8. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Park. Relat. Disord. 2011, 17:10-15.
9. Heetun Z.S., Quigley E.M. Gastroparesis and Parkinson's disease: a systematic review. Park. Relat. Disord. 2012, 18:433-440.
10. Phillips R.J., Walter G.C., Wilder S.L., Baronowsky E.A., Powley T.L. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease?. Neuroscience 2008, 153:733-750.
11. Toti L., Travagli R.A. Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis. Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 307:G1013-G1023.
12. MacGregor I.L., Martin P., Meyer J.H. Gastric emptying of solid food in normal man and after subtotal gastrectomy and truncal vagotomy with pyloroplasty. Gastroenterology 1977, 72:206-211.
13. Gjerloff T., Fedorova T., Knudsen K., Munk O.L., Nahimi A., Jacobsen S., Danielsen E.H., Terkelsen A.J., Hansen J., Pavese N., Brooks D.J., Borghammer P. Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain 2015, 138:653-663.
14. Furness J.B. The enteric nervous system and neurogastroenterology. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:286-294.
15. Furness J.B., Callaghan B.P., Rivera L.R., Cho H.J. The enteric nervous system and gastrointestinal innervation: integrated local and central control. Adv. Exp. Med. Biol. 2014, 817:39-71.
16. Grundy D., Al-Chaer E.D., Aziz Q., Collins S.M., Ke M., Taché Y., Wood J.D. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006, 130:1391-1411.
17. Kaneoke Y., Koike Y., Sakurai N., Washimi Y., Hirayama M., Hoshiyama M., Takahashi A. Gastrointestinal dysfunction in Parkinson's disease detected by electrogastroenterography. J. Auton. Nerv. Syst. 1995, 50:275-281.
18. Krygowska-Wajs A., Lorens K., Thor P., Szczudlik A., Konturek S. Gastric electromechanical dysfunction in Parkinson's disease. Funct. Neurol. 2000, 15:41-46.
19. Robertson D.R., Renwick A.G., Wood N.D., Cross N., Macklin B.S., Fleming J.S., Waller D.G., George C.F. The influence of levodopa on gastric emptying in man. Br. J. Clin. Pharmacol. 1990, 29:47-53.
20. Tanaka Y., Kato T., Nishida H., Yamada M., Koumura A., Sakurai T., Hayashi Y., Kimura A., Hozumi I., Araki H., Murase M., Nagaki M., Moriwaki H., Inuzuka T. Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test. J. Neurol. 2011, 258:421-426.
21. Suzuki M., Kurita A., Hashimoto M., Fukumitsu N., Abo M., Ito Y., Urashima M., Inoue K. Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J. Neurol. Sci. 2006, 240:15-19.
22. Tanaka Y., Kato T., Nishida H., Yamada M., Koumura A., Sakurai T., Hayashi Y., Kimura A., Hozumi I., Araki H., Murase M., Nagaki M., Moriwaki H., Inuzuka T. Is there delayed gastric emptying in patients with multiple system atrophy? An analysis using the (13)C-acetate breath test. J. Neurol. 2012, 259:1448-1452.
23. Cersosimo M.G. Gastrointestinal biopsies for the diagnosis of alpha-synuclein pathology in Parkinson's disease. Gastroenterol. Res. Pract. 2015, 2015:476041.
24. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv. Neurol. 1987, 45:1-18.
25. Del Tredici K., Rub U., De Vos R.A., Bohl J.R., Braak H. Where does Parkinson's disease pathology begin in the brain?. J. Neuropathol. Exp. Neurol. 2002, 61:413-426.
26. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
27. Braak H., Bohl J.R., Muller C.M., Rub U., de Vos R.A., Del Tredici K. Stanley Fahn lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 2006, 21:2042-2051.
28. Hawkes C.H., Del Tredici K., Braak H. A timeline for Parkinson's disease. Park. Relat. Disord. 2010, 16:79-84.
29. Sanger G.J., Lee K. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders. Nat. Rev. Drug Discov. 2008, 7:241-254.
30. Khoo J., Rayner C.K., Feinle-Bisset C., Jones K.L., Horowitz M. Gastrointestinal hormonal dysfunction in gastroparesis and functional dyspepsia. Neurogastroenterol. Motil. 2010, 22:1270-1278.
31. Raybould H.E., Tache Y. Cholecystokinin inhibits gastric motility and emptying via a capsaicin-sensitive vagal pathway in rats. Am. J. Physiol. 1988, 255:G242-G246.
32. Fujii C., Harada S., Ohkoshi N., Hayashi A., Yoshizawa K., Ishizuka C., Nakamura T. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin. Genet. 1999, 56:394-399.
33. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., Dhillo W.S., Ghatei M.A., Bloom S.R. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 2001, 86:5992.
34. Williams D.L., Grill H.J., Cummings D.E., Kaplan J.M. Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 2003, 144:5184-5187.
35. Unger M.M., Moller J.C., Mankel K., Eggert K.M., Bohne K., Bodden M., Stiasny-Kolster K., Kann P.H., Mayer G., Tebbe J.J., Oertel W.H. Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease?. J. Neurol. 2011, 258:982-990.
36. Arai E., Arai M., Uchiyama T., Higuchi Y., Aoyagi K., Yamanaka Y., Yamamoto T., Nagano O., Shiina A., Maruoka D., Matsumura T., Nakagawa T., Katsuno T., Imazeki F., Saeki N., Kuwabara S., Yokosuka O. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease. Brain 2012, 135:1478-1485.
37. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53--> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8968-8973.
38. Shimoji M., Zhang L., Mandir A.S., Dawson V.L., Dawson T.M. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. Brain Res. Mol. Brain Res. 2005, 134:103-108.
39. Blesa J., Phani S., Jackson-Lewis V., Przedborski S. Classic and new animal models of Parkinson's disease. J. Biomed. Biotechnol. 2012, 2012:845618.
40. Alam M., Schmidt W.J. Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson's disease. Physiol. Behav. 2004, 83:395-400.
41. Drolet R.E., Cannon J.R., Montero L., Greenamyre J.T. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol. Dis. 2009, 36:96-102.
42. Blandini F., Armentero M.T. Animal models of Parkinson's disease. FEBS J. 2012, 279:1156-1166.
43. Hunter R.L., Cheng B., Choi D.Y., Liu M., Liu S., Cass W.A., Bing G. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J. Neurosci. Res. 2009, 87:1913-1921.
44. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schöls L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
45. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
46. Anderson G., Noorian A.R., Taylor G., Anitha M., Bernhard D., Srinivasan S., Greene J.G. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp. Neurol. 2007, 207:4-12.
47. Tasselli M., Chaumette T., Paillusson S., Monnet Y., Lafoux A., Huchet-Cadiou C., Aubert P., Hunot S., Derkinderen P., Neunlist M. Effects of oral administration of rotenone on gastrointestinal functions in mice. Neurogastroenterol. Motil. 2013, 25:e183-193.
48. Greene J.G., Noorian A.R., Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp. Neurol. 2009, 218:154-161.
49. Zheng L.F., Wang Z.Y., Li X.F., Song J., Hong F., Lian H., Wang Q., Feng X.Y., Tang Y.Y., Zhang Y., Zhu J.X. Reduced expression of choline acetyltransferase in vagal motoneurons and gastric motor dysfunction in a 6-OHDA rat model of Parkinson's disease. Brain Res. 2011, 1420:59-67.
50. Zhu H.C., Zhao J., Luo C.Y., Li Q.Q. Gastrointestinal dysfunction in a Parkinson's disease rat model and the changes of dopaminergic, nitric oxidergic, and cholinergic neurotransmitters in myenteric plexus. J. Mol. Neurosci. 2012, 47:15-25.
51. Vegezzi G., Al Harraq Z., Levandis G., Cerri S., Blandini F., Gnudi G., Miduri F., Blandizzi C., Domenichini G., Bertoni S., Ballabeni V., Barocelli E. Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: comparative study with conventional in vivo techniques in the rat. J. Pharmacol. Toxicol. Methods 2014, 70:163-169.
52. Zheng L.F., Song J., Fan R.F., Chen C.L., Ren Q.Z., Zhang X.L., Feng X.Y., Zhang Y., Li L.S., Zhu J.X. The role of the vagal pathway and gastric dopamine in the gastroparesis of rats after a 6-hydroxydopamine microinjection in the substantia nigra. Acta Physiol. 2014, 211:434-446.
53. Zheng L.F., Zhang Y., Chen C.L., Song J., Fan R.F., Cai Q.Q., Wang Z.Y., Zhu J.X. Alterations in TH- and ChAT-immunoreactive neurons in the DMV and gastric dysmotility in an LPS-induced PD rat model. Auton. Neurosci. 2013, 177:194-198.
54. Song J., Zheng L., Zhang X., Feng X., Fan R., Sun L., Hong F., Zhang Y., Zhu J. Upregulation of beta1-adrenoceptors is involved in the formation of gastric dysmotility in the 6-hydroxydopamine rat model of Parkinson's disease. Transl. Res. 2014, 164:22-31.
55. Colucci M., Cervio M., Faniglione M., De Angelis S., Pajoro M., Levandis G., Tassorelli C., Blandini F., Feletti F., De Giorgio R., Dellabianca A., Tonini S., Tonini M. Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. Auton. Neurosci. 2012, 169:77-86.
56. Li Z.S., Schmauss C., Cuenca A., Ratcliffe E., Gershon M.D. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J Neurosci. 2006, 26:2798-2807.
57. Takahashi A. Autonomic nervous system disorders in Parkinson's disease. Eur. Neurol. 1991, 31(Suppl. 1):41-47.
58. Tian Y.M., Chen X., Luo D.Z., Zhang X.H., Xue H., Zheng L.F., Yang N., Wang X.M., Zhu J.X. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease. Neuroscience 2008, 153:634-644.
59. Nagahata Y., Azumi Y., Kawakita N., Wada T., Saitoh Y. Inhibitory effect of dopamine on gastric motility in rats. Scand. J. Gastroenterol. 1995, 30:880-885.
60. Saur D., Neuhuber W.L., Gengenbach B., Huber A., Schusdziarra V., Allescher H.D. Site-specific gene expression of nNOS variants in distinct functional regions of rat gastrointestinal tract. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282:G349-G358.
61. Gasser T. Update on the genetics of Parkinson's disease. Mov. Disord. 2007, 22(Suppl. 17):S343-S350.
62. Lebouvier T., Neunlist M., Bruley des Varannes S., Coron E., Drouard A., N'Guyen J.M., Chaumette T., Tasselli M., Paillusson S., Flamand M., Galmiche J.P., Damier P., Derkinderen P. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PloS One 2010, 5:e12728.
63. Noorian A.R., Rha J., Annerino D.M., Bernhard D., Taylor G.M., Greene J.G. Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. Neurobiol. Dis. 2012, 48:9-19.
64. Kuo Y.M., Li Z., Jiao Y., Gaborit N., Pani A.K., Orrison B.M., Bruneau B.G., Giasson B.I., Smeyne R.J., Gershon M.D., Nussbaum R.L. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 2010, 19:1633-1650.
65. Hilton D., Stephens M., Kirk L., Edwards P., Potter R., Zajicek J., Broughton E., Hagan H., Carroll C. Accumulation of alpha-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. Acta Neuropathol. 2014, 127:235-241.
66. Trinh J., Farrer M. Advances in the genetics of Parkinson disease. Nat. Rev. Neurol. 2013, 9:445-454.
67. Visanji N.P., Brooks P.L., Hazrati L.N., Lang A.E. The prion hypothesis in Parkinson's disease: braak to the future. Acta Neuropathol. Commun. 2013, 1:2.
68. Braak H., Rüb U., Gai W.P., Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 2003, 110:517-536.
69. Braak H., Ghebremedhin E., Rüb U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318:121-134.
70. Zheng Z., Travagli R.A. Dopamine effects on identified rat vagal motoneurons. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G1002-G1008.